Peptide Clinical Trials Explained

ClinicalTrials.gov is the US registry of clinical studies. It is free, public, and the fastest way to establish whether a compound has a real development programme behind it.

Start with the search

Search the compound name and also its development code — trials are frequently registered under the code rather than the marketed name. Retatrutide appears under both "retatrutide" and "LY3437943".

For most compounds sold as research peptides, this search returns nothing. That is not a limitation of the registry. It is the finding.

Reading a trial record

Status

• Recruiting / Active, not recruiting — the programme is running.
• Completed — finished. Results may or may not be posted; check the Results section, and search the literature separately.
• Terminated / Withdrawn / Suspended — stopped. The record usually gives a reason, and that reason is often the most informative sentence on the page.
• Unknown status — the sponsor has not updated the record past its expected completion date. In practice this usually means the trial quietly stopped.

Phase

Phase 1 asks whether a compound is tolerable and what the body does to it. Phase 2 looks for a signal and establishes dose. Phase 3 tests whether it works, in a population large enough to be confident. See how FDA drug approval works for what each stage can and cannot establish.

Enrolment

The number of participants, and whether the figure is actual or estimated. An "estimated" enrolment on a trial that closed years ago means it may never have enrolled anyone.

Primary outcome measure

The most important field on the page. This is what the trial was designed and powered to detect. Anything else it reports is secondary — informative, but not what the trial was built to answer.

Sponsor

Pharmaceutical company, academic institution, or a small entity that exists only for this trial. Each implies a different level of resourcing and a different probability of completion.

Last update posted

An active programme updates its records. A trial last touched in 2011 is a historical document.

What a registry record does not tell you

That the trial happened as described. Registration precedes conduct. Some registered trials never enrol.

What the results were. Results posting is required in some circumstances and not others, and compliance is imperfect. Absence of posted results does not mean absence of results — it frequently means the results were disappointing and never written up.

That the compound works. A listed Phase 2 trial establishes that someone thought the question worth asking.

Applying it to peptides

Three quick cases from this site's library:

Retatrutide — multiple registered Phase 3 trials with large enrolments and an active pharmaceutical sponsor. An unambiguously live programme.

Ipamorelin — registered trials in postoperative ileus, completed, with a published Phase 2 result that missed its primary endpoint. A programme that ran, produced an answer, and stopped.

BPC-157 — no active registered programme identified. The early-phase work described in the literature predates modern registration requirements and produced no published results.

Those three states — active, concluded, absent — cover most of what anyone needs to know about where a compound stands, and the registry gives all three in about ninety seconds.

A note on trial participation

Clinical trials are how medicine finds out whether things work, and participation is a genuine contribution. If you are considering it, the registry lists eligibility criteria and contact details for each study. That is a conversation to have with a clinician, and it is categorically different from buying an investigational compound online — which delivers the risk of an experimental drug without the screening, the pharmaceutical-grade material, the monitoring, or the knowledge that makes the risk worth taking.